AS GLP-1s ORIGINALLY INTENDED TO TREAT TYPE 2 DIABETES (T2D) AND OFTEN DELIVERED WITH INJECTION PENS DEVELOPED FOR INSULIN ARE INCREASINGLY USED TO TREAT OBESITY, PERHAPS IT IS WORTH RETHINKING THE BASIS OF THESE DESIGNS TO ACCOMMODATE A USER GROUP THAT MAY HAVE DIFFERENT REQUIREMENTS. People with diabetes depend on these devices for survival, and the devices have been optimised accordingly for their ease of use, safety and reliability
How will dosing be adjusted
If BPC-157 increased cancer risk by a small percentage, the effect might not be noticeable without systematic tracking across thousands of users over many years
Importantly, the study showed consistent results across scales, maintaining product quality while increasing batch sizes
Lawmakers want to add more Chinese biotechs to defense list Roivant announced that an autoimmune drug it acquired from Pfizer succeeded in a Phase 2 trial
Chris Stallman, MLS, MS is a certified genetic counselor, Program Director of the University of Arizona Genetic Counseling Graduate Program, and Director of MotherToBaby Arizona
